Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2875358 plus erlotinib in EGFR-mutant NSCLC
NCT01897480Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of emibetuzumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Aug 2013; status: completed.
02
Drugs
emibetuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01897480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897480.